Latest News

MIAMI, FL – February 15, 2024 – A study co-led by researchers at Miami Cancer Institute, part of Baptist Health South Florida, found that ablative stereotactic magnetic resonance (MR)-guided adaptive radiation therapy may improve local control (LC) and overall survival (OS) in patients with borderline resectable (BRPC) and locally advanced...
NEW YORK — Scientists at Weill Cornell Medical College have developed a new mouse model of Parkinson’s disease (PD) that successfully reproduces the impairments of movement and the degenerative brain changes that occur in the human disease. Their research, performed in collaboration with investigators at Columbia University Medical Center, appears...
Last week, the Michigan House passed (88-20) House Bill 4167, which would create a Rare Disease Advisory Council (RDAC) within Michigan’s Department of Health and Human Services (MDHHS). The council would be required to conduct research, identify priorities, and make policy recommendations regarding access, treatments, and services for rare diseases...
Bozeman, Mont. and Vancuver, BC — Microbion Corporation announced that the US Patent and Trademark Office (USPTO) issued United States Patent No. 11,464,749 to Microbion with claims to the use of Microbion’s proprietary pravibismane inhaled composition for treatment of pulmonary infections. The patent, entitled “Bismuth-thiol compositions and methods of use,”...
BOZEMAN, MT and VANCOUVER, BC – Microbion Corporation today announced that the company has been granted a second orphan drug designation for its lead drug candidate, pravibismane, for the treatment of non-tuberculous mycobacterial (NTM) infections. NTM infections are most commonly found in the lungs; however, skin and soft tissue, indwelling...
Luxembourg – The accumulation of pathological proteins is a hallmark of several neurodegenerative disorders, including Alzheimer’s disease, frontotemporal dementia and Parkinson’s disease. Proteins such as alpha-synuclein and tau can abnormally aggregate inside neurons, disrupting essential cellular function. “We knew that microglia play a role in clearing these protein aggregates but...
BERLIN — Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced that the German Multicenter ALL Study Group (GMALL) presented phase 2 clinical data of the BiTE(R) antibody blinatumomab (MT103) at the 14th Congress of the European Hematology...
A new study suggests that delivering small RNAs, known as microRNAs, to cancer cells could help to stop the disease in its tracks. microRNAs control gene expression and are commonly lost in cancerous tumors. Researchers have shown that replacement of a single microRNA in mice with an extremely aggressive form...